Therapeutic effects of nedaplatin combined with Astragalus polysaccharide by consistent intrathoracic medication on malignant pleural effusion caused by lung cancer
SU Peng
CHEN Haiyang
Abstract：Objective To observe the therapeutic effects of nedaplatin combined with Astragalus polysaccharide by consistent intrathoracic medication on malignant pleural effusion caused by lung cancer.Methods Ninety patients with malignant pleural effusion caused by lung cancer were randomly divided into research group and control group,with 45 patients in each group.The patients in research group were treated by nedaplatin combined with Astragalus polysaccharide by means of consistent intrathoracic medication, however, the patients in control group were treated by nedaplatin intraperitoneal perfusion only.The therapeutic effect,life quality of patients, drug related adverse reactions were observed for both groups,moreover,the levels of T lymphocyte subsets,immunoglobulins, PKM2 and SOD were detected and compared between two groups.Results After treatment,the effective rate in research group was significantly higher than that in control group (P<0.05).The life quality of patients was evaluated by HAMA,Barthel index and VAS scores,and there were no significant differences in HAMA,Barthel index,VAS scores before treatment between two groups (P>0.05),after treatment,HAMA and VAS scores were obviously decreased, however, Barthel indexes were significantly increased (P<0.05),moreover, the indexes including HAMA,Barthel index,VAS scores in research group were superior to those in control group (P<0.05).The incidence rates of drug related adverse reactions in research group were significantly lower than those in control group (P<0.05).Before treatment there were no significant differences in T lymphocyte subsets,immunoglobulins and PKM2 between 2 groups (P>0.05).After treatment,PKM2 in research group was obviously decreased (P<0.05), but the other indexes were significantly increased,as compared with those before treatment (P<0.05).However the levels of IgG in control group were higher than those before treatment,but the levels of CD+3 and CD+4 were significantly decreased,moreover there were no significant differences in CD+4/CD+8 and IgM before treatment and after treatment (P>0.05).After treatment there was no significant difference in CD+4/CD+8 between two groups (P>0.05),however,the other indexes in research group were significantly higher than those in control group (P<0.05).Conclusion The therapeutic effects of nedaplatin combined with Astragalus polysaccharide by means of consistent intrathoracic medication on malignant pleural effusion caused by lung cancer are superiorto those by nedaplatin medication only,which can effectively improve the immunity stress status of patients,therefor,which is worth using widely in clinical practice.
Keywords：lung cancerpleural effusionnedaplatinAstragalus polysaccharidetreatment outcome
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 2423-2427 )